Clinical outcome of initially unresectable pancreatic cancer patients: Conversion surgery after modified FOLFIRINOX or gemcitabine nab-paclitaxel

被引：0
|
作者：
Ushida, Yuta [1 ]
Inoue, Yosuke [1 ]
Ito, Hiromichi [1 ]
Ono, Yoshihiro [1 ]
Sato, Takafumi [1 ]
Takahashi, Yu [1 ]
机构：
[1] Japanese Fdn Canc Res, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
725
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
  • [2] Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
    Muranaka, Tetsuhito
    Kuwatani, Masaki
    Komatsu, Yoshito
    Sawada, Kentaro
    Nakatsumi, Hiroshi
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Kubota, Yoshimasa
    Kubo, Kimitoshi
    Kawahata, Shuhei
    Kawakubo, Kazumichi
    Kawakami, Hiroshi
    Sakamoto, Naoya
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 566 - 571
  • [3] Pathologic and clinical outcomes after neoadjuvant modified FOLFIRINOX and gemcitabine and NAB-paclitaxel for pancreatic cancer.
    Markabawi, Danny
    Ianiro, Cora
    Burton, Jeffrey
    Bolton, Nathan
    Mizrahi, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16236 - E16236
  • [4] ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
    Yuta Ushida
    Yosuke Inoue
    Atsushi Oba
    Takafumi Mie
    Hiromichi Ito
    Yoshihiro Ono
    Takafumi Sato
    Masato Ozaka
    Takashi Sasaki
    Akio Saiura
    Naoki Sasahira
    Yu Takahashi
    Annals of Surgical Oncology, 2022, 29 : 5051 - 5052
  • [5] ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
    Ushida, Yuta
    Inoue, Yosuke
    Oba, Atsushi
    Mie, Takafumi
    Ito, Hiromichi
    Ono, Yoshihiro
    Sato, Takafumi
    Ozaka, Masato
    Sasaki, Takashi
    Saiura, Akio
    Sasahira, Naoki
    Takahashi, Yu
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (08) : 5051 - 5052
  • [6] FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
    Matsumoto, Toshihiko
    Kurioka, Yusuke
    Okazaki, Ukyo
    Matsuo, Yu
    Kimura, Shogo
    Miura, Kou
    Tsuduki, Takao
    Takagi, Shinjiro
    Takatani, Masahiro
    Morishita, Hirofumi
    PANCREAS, 2020, 49 (04) : 574 - 578
  • [7] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
    Hino, Kaori
    Nishina, Tomohiro
    Numata, Yuuki
    Asagi, Akinori
    Inoue, Tomonori
    Yoshimatsu, Megumi
    Sakaguchi, Chihiro
    Nakasya, Akio
    Nishide, Norifumi
    Kajiwara, Takeshi
    Terao, Takashi
    Nadano, Seijin
    Marui, Kaori
    Okujima, Yusuke
    Kokubu, Masahito
    Imamura, Yoshiki
    Kanemitsu, Kozue
    Koizumi, Mitsuhito
    Kumagi, Teru
    Hiasa, Yoichi
    Hyodo, Ichinosuke
    INTERNAL MEDICINE, 2022, 61 (15) : 2255 - 2261
  • [9] Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1)
    Okano, Naohiro
    Kawai, Manabu
    Ueno, Makoto
    Yu, Xianjun
    Inoue, Yosuke
    Takahashi, Shinichiro
    Wang, Wenquan
    Takahashi, Hidenori
    Okamura, Yukiyasu
    Morinaga, Soichiro
    Matsumoto, Ippei
    Shimizu, Yasuhiro
    Yoshida, Kazuhiro
    Yamamoto, Tomohisa
    Ohtsuka, Masayuki
    Inokawa, Yoshikuni
    Nara, Satoshi
    Tamura, Jun
    Shinoda, Satoru
    Yamamoto, Kouji
    Yamaue, Hiroki
    Furuse, Junji
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2024, 31 (11) : 816 - 829
  • [10] Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report
    Okura, Ryosuke
    Takano, Shigetsugu
    Yokota, Tetsuo
    Yoshitomi, Hideyuki
    Kagawa, Shingo
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Suzuki, Daisuke
    Sakai, Nozomu
    Nojima, Hiroyuki
    Mishima, Takashi
    Miyazaki, Masaru
    Ohtsuka, Masayuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (04) : 389 - 393
12345